Phenotypes Associated with This Genotype

Genotype
MGI:3706961

• Allelic Composition: Wwox^tm1Ria/Wwox⁺
• Genetic Background: involves: 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Tumor phenotype in Wwox^tm1Ria/Wwox⁺ mice

neoplasm

increased tumor incidence ( J:120064 )

• 5-fold increase in tumor incidence and in number of tumors per mouse compared to wild-type mice

• mice develop multiple types of spontaneous tumors including liver hemangioma and lymphoma infiltrations in the internal organs not seen in wild-type mice

• spontaneous tumors with increased incidence include centroblastic lymphoma (10%) and Burkitts cell lymphoma (5%)

• however, the incidence of spontaneous large cell lymphomas is the same as in wild-type

increased incidence of tumors by chemical induction ( J:120064 )

• ENU-induced (20 mg/kg) tumor incidence isincreased to 80% compared to 48% in wild-type mice

• ENU treated heterozygotes have increased lung cancer incidence (72%) lymphoma incidence (59%) and incidence of other tumors (20%) compared to treated wild-type mice (36%, 31%, and 2.4%, respectively)

• ENU-induced lung tumor multiplicity (83) and lymphoma aggressiveness (63) are increased compared to treated wild-type mice (31 and 32, respectively)

• a number of other tumors are found only in ENU-treated heterozygotes including liver hemangiomas (11%), chondrosarconmas (2%), fibroadenomas (2%), squamous cell carcinomas (4%) and lymphoma infiltrate in internal organs, mainly livers and lungs (9%)

increased lung tumor incidence ( J:120064 )

• incidence of spontaneous lung papillary carcinomas is 15.5% compared to 3.3% in wild-type mice

hematopoietic system

enlarged spleen ( J:120064 )

• 59% of ENU-treated heterozygotes present with enlarged spleens compared to 31% in treated wild-type with the presence of atypia of the malignant lymphoblasts

• proliferating lymphocytes were largely B220+/IgM+ B cells

immune system

enlarged spleen ( J:120064 )

• 59% of ENU-treated heterozygotes present with enlarged spleens compared to 31% in treated wild-type with the presence of atypia of the malignant lymphoblasts

• proliferating lymphocytes were largely B220+/IgM+ B cells

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:120064 )

• ENU-induced (20 mg/kg) tumor incidence isincreased to 80% compared to 48% in wild-type mice

• ENU treated heterozygotes have increased lung cancer incidence (72%) lymphoma incidence (59%) and incidence of other tumors (20%) compared to treated wild-type mice (36%, 31%, and 2.4%, respectively)

• ENU-induced lung tumor multiplicity (83) and lymphoma aggressiveness (63) are increased compared to treated wild-type mice (31 and 32, respectively)

• a number of other tumors are found only in ENU-treated heterozygotes including liver hemangiomas (11%), chondrosarconmas (2%), fibroadenomas (2%), squamous cell carcinomas (4%) and lymphoma infiltrate in internal organs, mainly livers and lungs (9%)

respiratory system

increased lung tumor incidence ( J:120064 )

• incidence of spontaneous lung papillary carcinomas is 15.5% compared to 3.3% in wild-type mice

growth/size/body

enlarged spleen ( J:120064 )

• 59% of ENU-treated heterozygotes present with enlarged spleens compared to 31% in treated wild-type with the presence of atypia of the malignant lymphoblasts

• proliferating lymphocytes were largely B220+/IgM+ B cells